A study published in Neurotherapeutics dives into the role of the gut microbiome in the pathogenesis and progression of multiple sclerosis (MS), a chronic | Drug Discovery And Development ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in on FDA approval.

Three investigators and their teams have each received €100,000 funding for clinical trial development projects as part of the International Progressive MS Alliance’s Experimental Medicine Trial ...

What if, rather than focusing solely on the drivers of disease (pathogenesis), we also explored the factors sustaining our ...

The COVID incubation period can range from two to 14 days. On average, it takes 3-5 days to start developing symptoms after a ...

Cuprizone is a neurotoxin with copper-chelating ability, and it produces symptoms that are similar to those caused by multiple sclerosis lesions. Multiple sclerosis induced by cuprizone in animal ...

Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX ...

2 Second, scientists investigating MS pathogenesis confirmed that the natural history of MS could be altered with an immunomodulating approach, generating a rationale for the clinical use of ...

A joint study between the University of Oklahoma Health Sciences Center (Oklahoma City, Oklahoma) and the UC Davis West Coast Metabolomics Center (Davis, California) identified differentially ...

UB researchers have compiled a list of words physicians should never say to patients with complex, chronic disorders that are ...

especially multiple sclerosis. Herpes simplex encephalitis caused by HSV-1 is a common viral encephalitis with severe symptoms and poor prognosis. Here, the authors developed a new 3D human ...